Atorvia is a pre-clinical stage biotech company fearlessly tackling kidney failure. We are advancing a pipeline of engineered therapeutics that inhibit protein:protein interactions in the cell that cause cell death and organ failure. Our groundbreaking research is uncovering novel functions of known proteins and allowing us to identify structural changes that take place when cells are under stress. We are leveraging these proteomic insights to uncover potential new ways of diagnosing, preventing and treating kidney failure and engineer small peptide therapeutics to specifically target the root cause.